Page 2 - Cancer Treatment

Can a simple sugar like glucose supercharge body's cancer-fighting T cells?

A new study reveals that glucose not only fuels energy but also equips immune T cells with tools to better organise and destroy cancer cells

This new compound may help treat aggressive triple-negative breast cancer

Researchers at IIT Guwahati and IASST have designed a novel compound showing promise against aggressive triple-negative breast cancer

GSK enters into oncology segment; launches therapies for gynae cancers

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies for gynaecological cancers. The company has introduced advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in the country. "These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women's cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India," GSK India MD Bhushan Akshikar said in a statement. Gynaecological cancers are among the most common cancers in women in India. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78 per cent and 69 per cent, respectively. Endometrial cancer is a malignancy arising out of the endometrium, the inner lining of the uterus. Nearly a fourth of endometrial cancer patients in India are at an advanced stage where chemotherapy remains a standa

Could this tiny genetic mutation be making humans more prone to cancer?

A mutation in the immune protein FasL may make humans more vulnerable to solid tumours, but scientists say it could be fixed through combination immunotherapy

This is what 'magic mushrooms' do to cancer patients with depression

A new study finds that psilocybin, the hallucinogenic compound in magic mushrooms, can offer long-term relief from depression and anxiety in cancer patients

Glenmark set to launch blood cancer treatment drug Brukinsa in India

Glenmark will introduce Brukinsa, a BTK inhibitor developed by BeOne Medicines, in India after DCGI approval to treat five B-cell blood cancers with proven safety and efficacy

Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment

Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain ...

Joe Biden's prostate cancer: Risks, symptoms, treatment options explained

Joe Biden's metastatic or stage 4 prostate cancer diagnosis highlights common symptoms, risk factors, and treatment options men should know about

12 common cancer myths busted: What doctors say you must stop believing

Fact-check Friday: Doctors debunk persistent cancer myths-from sugar and deodorants to breast surgery and mobile phones-that often mislead patients, delay diagnosis, and derail treatment decisions

US doctors remove spinal tumour through eye socket in world-first surgery

In a medical first, US surgeons removed a spinal tumour through a patient's eye socket, a procedure that is being seen as a new hope for treating complex, hard-to-reach tumours with less risk

This cancer therapy stunned researchers. Here's what the trial revealed

Phase-I trial of HSPCAR30 therapy shows 100% response and 50% remission in CD30+ lymphoma patients with no major side effects, boosting hope for targeted, affordable cancer treatment

Cancer treatment top priority for govt, Rs 3K cr allocated, says Nadda

Union Health Minister JP Nadda on Sunday said cancer treatment is a top priority area for policy makers and a sum of Rs 3000 crore has been allocated for the purpose. He was speaking after inaugurating the Truebeam facility (linear accelerator used in radiation oncology) at the State Cancer Institute here. "We have made cancer treatment top priority. We have increased our baseline for screening and detection. In 1,75,000 Ayushman Arogya Mandirs (AAMs), screening for oral, breast and cervical cancer has been conducted. We have made the age of 30 mandatory for screening. Cancer treatment is a priority area for policy makers and we have allocated Rs 3000 crore for the purpose," he said. Nadda said more than 26 crore people have been screened for oral cancer, following which 1.63 lakh cases were detected. "As many as 14.6 crore people were screened for breast cancer, resulting in 57,179 detections. More than 9 crore people were screened for cervical cancer, and 96,973 persons were ...

Hope after chemo: Lymph node removal may boost ovarian cancer survival

A recent study by Aiims, Delhi suggests that removing lymph nodes after chemotherapy may significantly improve survival rates among ovarian cancer patients

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio

Jobevne works by blocking a protein called VEGF, which helps tumours grow new blood vessels

World Health Day: Conduct a thorough checkup of your health insurance

Ensure the policy offers adequate sum insured to deal with even critical illnesses, and move out of policies with sub-limits

China unveils booster to amplify immune responses against cancer, viruses

This technology is capable of amplifying immune responses against tumours and infections up to 150-fold

Cancer, neonatal care, and genetic disorders dominate crowdfunding in India

CarePal, the parent company of Impact Guru, in its State of Cancer Fundraising Report 2024, revealed that the top 100 cancer campaigns on Impact Guru in FY24 raised an average of Rs 10 lakh each

King Charles III seen in public a day after hospitalisation for treatment

King Charles III was briefly hospitalised for observation on Thursday after experiencing "temporary side effects" related to a scheduled cancer treatment, Buckingham Palace said in a statement. His engagements for Thursday afternoon and Friday were cancelled. "His majesty has now returned to Clarence House and as a precautionary measure, acting on medical advice, tomorrow's diary programme will also be rescheduled," the palace said. "His majesty would like to send his apologies to all those who may be inconvenienced or disappointed as a result," it added. The king's health has been closely watched ever since early last year when he announced that he had been diagnosed with an undisclosed form of cancer. Charles, 76, stepped away from public duties for about three months but continued fulfilling state duties, such as reviewing government papers and meeting with the prime minister. Charles' cancer diagnosis has heaped pressure on the British monarchy, which is still evolving after

Apollo Hospitals partners with Ion Beam Applications for proton therapy

Apollo Hospitals on Tuesday said it has tied up with Ion Beam Applications to introduce proton beam therapy solutions for cancer treatment. The healthcare major has tied up with Ion Beam Applications to introduce the Proteus One system in India. "The addition of Proteus One to our Apollo Proton Cancer Centres further solidifies our position as a global leader in Proton Therapy. This next-generation technology will allow us to achieve superior clinical outcomes and significantly improve the quality of life for cancer patients in India and beyond," Apollo Hospitals Enterprise Founder-Chairman Prathap C Reddy said in a statement. As per the study published in The Lancet Regional Health, worldwide in terms of absolute incidence number, following China and the US, India ranks third, contributing 7.5 per cent of all new cancer incidences and is expected to grow to 1.5 million this year. Ion Beam Applications CEO Olivier Legrain said: "These contracts expand upon the close relationship we